Abstract

The “Healthy China 2030” Planning Outline is explicitly formulated to strengthen the supply guarantee and early warning of shortage drugs and to improve the drug reserve system and emergency supply mechanism. It is further specified by the 4th Plenary Session of the 20th Central Committee of the Communist Party of China that “the whole-chain supervision of drug safety” should be strengthened during the formulation of the 15^th Five-Year Plan. Through these institutional arrangements, the advancement of biopharmaceutical innovation and the process of high-quality development are expected to be promoted. Based on the analysis of Five-Year Plan formulation requirements, the current status of drug supply guarantee development, and regional policy goals during the Five-Year Plan period, regional drug safety guarantee policy goals and supply guarantee capabilities are assessed in this paper by means of Social Network Analysis (SNA) and the DEA-Malmquist evaluation method. The results indicate that during the 14^th Five-Year Plan period, the regional drug supply guarantee system was mainly focused on shortage drug management mechanisms, centralized drug procurement, medical devices and consumables, as well as clinical drug use monitoring and dynamic adjustment mechanisms. The Total Factor Productivity (TFP) of the pharmaceutical manufacturing industry was found to have grown most rapidly during the 13th Five-Year Plan period (2016-2020); however, although the TFP of the pharmaceutical manufacturing industry increased by an average of 8.1% annually in the early stage of the 14^th Five-Year Plan (2021-2023), the growth rate slowed down, and the TFP of various regions decreased compared with that of the 13^th Five-Year Plan period. Based on regional drug supply guarantee policy requirements and guarantee capability evaluation results, the main tasks for drug safety guarantee during the 15^th Five-Year Plan period are proposed, including drug safety traceability management, digital scenario practice, structural optimization of clinical medical products, patient medication education, and popular science publicity.

This work is licensed under a Creative Commons Attribution 4.0 License.